神経栄養性角膜炎の世界市場2020-2026:治療種類別(保存料なし人工涙液、局所抗生物質、羊膜移植、足根膜、組換えヒト神経成長因子(rhNGF)、その他)、地域別

◆英語タイトル:Global Neurotrophic Keratitis Market Size study, by Treatment Type (Preservative Free Artificial Tears, Topical Antibiotics, Amniotic Membrane Transplantation, Tarsorrhaphy, Recombinant Human Nerve Growth Factor (rhNGF), Others) and Regional Forecasts 2020-2026
◆商品コード:BZW20JN001
◆発行会社(リサーチ会社):Bizwit Research & Consulting
◆発行日:2020年4月10日
◆ページ数:約200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥650,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はBizwit Research & Consulting社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Bizwit Research & Consulting社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、神経栄養性角膜炎の世界市場について調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、治療種類別(保存料なし人工涙液、局所抗生物質、羊膜移植、足根膜、組換えヒト神経成長因子(rhNGF)、その他)分析、地域別分析、競争状況などを含め、次の構成でお届け致します。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・神経栄養性角膜炎の世界市場:治療種類別(保存料なし人工涙液、局所抗生物質、羊膜移植、足根膜、組換えヒト神経成長因子(rhNGF)、その他)
・神経栄養性角膜炎の世界市場:地域別
・競争状況
【レポートの概要】

Global Neurotrophic Keratitis Market is valued approximately USD 92 million in 2019 and is anticipated to grow with a healthy growth rate of more than 17% over the forecast period 2019-2026. Neurotrophic Keratitis (NK) is a neurodegenerative disease caused by the injury of trigeminal nerve that affects the cornea of an eye. In this disease, the patient drops the corneal sensitivity and thus cornea is unprotected to damages without treatment. If this disease is not treated and diagnosed properly, the patient can loss permanent eye vision. The treatment of neurotrophic keratitis is done by a team that includes neurologists, ophthalmologists and corneal specialists. Treatments are available based on the severity of the disease. Neurotrophic Keratitis treatment comprises topical antibiotics, bandage contact lenses, preservative artificial tears, amniotic membrane transplantation, keratoplasty, Recombinant human nerve growth factor (rhNGF), and so on. Growing number of approvals for new product innovation from regulatory authorities, with the huge financial support to the researchers for developing novel treatments are the few factors responsible for high CAGR of the market over the forecast period. For instance, in August 2018, Dompe farmaceutici S.p.A. has received approval for cenegermin topical eyes drop from FDA, which is a recombinant human nerve growth factor for the therapy of neurotrophic keratitis. The cenegermin has also obtained an Orphan Drug designation, Breakthrough Therapy designation and Fast Track status from the FDA. This, in turn, is expected to accelerate the growth of Neurotrophic Keratitis market around the world. However, low healthcare budget in some of the developing countries is one of the major factors expected to hamper the growth of the market over the forecast period of 2020-2026.

The regional analysis of global Neurotrophic Keratitis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising product approvals, presence of well-established healthcare infrastructure, and increase in R&D activities in neurotrophic keratitis in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing geriatric population and increasing government investments in healthcare and R&D present in the countries like China and India.

Major market player included in this report are:
Allergan, Plc.
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Bayer AG
CooperVision
Dompe farmaceutici S.p.A.
Johnson & Johnson
Novartis AG
ReGenTree, LLC.
Walgreens

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment Type:
Preservative Free Artificial Tears
Topical Antibiotics
Amniotic Membrane Transplantation
Tarsorrhaphy
Recombinant Human Nerve Growth Factor (rhNGF)
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026

Target Audience of the Global Neurotrophic Keratitis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

【レポートの目次】

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Million)
1.2.1. Neurotrophic Keratitis Market, by Region, 2018-2026 (USD Million)
1.2.2. Neurotrophic Keratitis Market, by Treatment Type, 2018-2026 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Neurotrophic Keratitis Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Neurotrophic Keratitis Market Dynamics
3.1. Neurotrophic Keratitis Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Neurotrophic Keratitis Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Neurotrophic Keratitis Market, by Treatment Type
5.1. Market Snapshot
5.2. Global Neurotrophic Keratitis Market by Treatment Type, Performance – Potential Analysis
5.3. Global Neurotrophic Keratitis Market Estimates & Forecasts by Treatment Type 2016-2026 (USD Million)
5.4. Neurotrophic Keratitis Market, Sub Segment Analysis
5.4.1. Preservative Free Artificial Tears
5.4.2. Topical Antibiotics
5.4.3. Amniotic Membrane Transplantation
5.4.4. Tarsorrhaphy
5.4.5. Recombinant Human Nerve Growth Factor (rhNGF)
5.4.6. Others
Chapter 6. Global Neurotrophic Keratitis Market, Regional Analysis
6.1. Neurotrophic Keratitis Market, Regional Market Snapshot
6.2. North America Neurotrophic Keratitis Market
6.2.1. U.S. Neurotrophic Keratitis Market
6.2.1.1. Treatment Type breakdown estimates & forecasts, 2016-2026
6.2.2. Canada Neurotrophic Keratitis Market
6.3. Europe Neurotrophic Keratitis Market Snapshot
6.3.1. U.K. Neurotrophic Keratitis Market
6.3.2. Germany Neurotrophic Keratitis Market
6.3.3. Rest of Europe Neurotrophic Keratitis Market
6.4. Asia-Pacific Neurotrophic Keratitis Market Snapshot
6.4.1. China Neurotrophic Keratitis Market
6.4.2. India Neurotrophic Keratitis Market
6.4.3. Japan Neurotrophic Keratitis Market
6.4.4. Rest of Asia Pacific Neurotrophic Keratitis Market
6.5. Latin America Neurotrophic Keratitis Market Snapshot
6.5.1. Brazil Neurotrophic Keratitis Market
6.5.2. Mexico Neurotrophic Keratitis Market
6.6. Rest of The World Neurotrophic Keratitis Market
Chapter 7. Competitive Intelligence
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Allergan, Plc.
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Product Summary
7.2.1.5. Recent Developments
7.2.2. Abbott Laboratories, Inc.
7.2.3. Bausch & Lomb Incorporated
7.2.4. Bayer AG
7.2.5. CooperVision
7.2.6. Dompe farmaceutici S.p.A.
7.2.7. Johnson & Johnson
7.2.8. Novartis AG
7.2.9. ReGenTree, LLC.
7.2.10. Walgreens
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption

List of Tables
TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL NEUROTROPHIC KERATITIS MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL NEUROTROPHIC KERATITIS MARKET
TABLE 3. GLOBAL NEUROTROPHIC KERATITIS MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD MILLION)
TABLE 7. GLOBAL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY TREATMENT TYPE 2016-2026 (USD MILLION)
TABLE 8. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 9. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 10. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 11. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 12. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 13. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 14. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 15. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 16. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 17. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 18. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 19. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 20. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 21. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 22. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 23. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 24. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 25. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 26. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 27. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 28. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 29. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 30. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 31. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 32. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 33. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 34. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 35. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 36. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 37. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 38. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 39. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 40. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 41. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 42. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 43. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 44. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 45. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 46. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 47. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 48. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 49. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 50. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 51. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 52. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 53. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 54. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 55. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 56. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経栄養性角膜炎の世界市場2020-2026:治療種類別(保存料なし人工涙液、局所抗生物質、羊膜移植、足根膜、組換えヒト神経成長因子(rhNGF)、その他)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆